All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Impact of maintaining MRD negativity post-induction on survival outcomes in patients with B-ALL
Bookmark this article
|
A single-center retrospective analysis assessed the impact of dynamic MRD assessment on survival prediction in 65 patients with B-ALL.1 MRD was assessed after induction, consolidation, and every 3 months up to 3 years.1 Results from this analysis were published in Hematology by Chen et al.1
|
| Key learnings |
| Maintaining MRD− status post-induction was associated with improved median PFS (not reached vs 11.3 months; HR, 0.26; 95% CI, 0.13–0.51; p < 0.0001) vs not maintaining MRD– status. |
| Allo-HSCT improved median PFS (14.5 months vs 6.5 months; HR, 0.23; 95% CI, 0.07–0.82; p = 0.0039) and OS (not reached vs 17.8 months; HR, 0.25; 95% CI, 0.07–0.91; p = 0.0237) vs no allo-HSCT in patients unable to maintain MRD negativity. |
| Among high-risk patients (n = 46), maintaining MRD negativity was associated with improved median PFS (not reached vs 11.3 months; HR, 0.28; 95% CI, 0.09–0.48; p = 0.0016) vs patients who did not maintain MRD negativity. |
| Results from this analysis suggest that dynamic MRD assessment in patients with ALL, can be used to help predict survival outcomes, guide patient selection for allo-HSCT, and further risk stratify high-risk patients. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; B-ALL, B-cell acute lymphoblastic leukemia; CI, confidence interval; HR, hazard ratio; MRD, measurable residual disease; OS, overall survival; PFS, progression-free survival.
- Chen Y, Liu, R, Li J. The significance of MRD-based strategy by dynamic assessment to guide treatment decisions in B-ALL - the enlightenment provided by demonstrating survival differences in the retrospective study. 2024;29(1):2415589. DOI: 10.1080/16078454.2024.2415589
More about...
Your opinion matters
6 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox